Allergy Shot for Adults: Candidacy, Comorbidities, and the Commitment
Allergy shots (SCIT) for adults have no formal upper age limit — the limiting factor is comorbidity, not chronology, per Cox 2011 PP3. Adults on beta-blockers face a relative contraindication because the drug may impair epinephrine response during a systemic reaction. Tkacz 2021 (n=103,207) found 23.9% of adults never returned after the first injection; only 43.9% reached maintenance — adherence is the largest real-world drag on efficacy.
6 peer-reviewed sources
Allergy shots work for adults of any age with no formal upper limit. The key contraindications are active uncontrolled asthma, active autoimmune disease, and beta-blocker therapy. A 3-to-5-year course can produce remission lasting years after stopping.
The essentials
Allergy shots (SCIT) for adults have no formal upper age limit — what matters is the comorbidity profile, not the birth year. The AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L et al., JACI 2011;127(1 Suppl):S1–S55; DOI 10.1016/j.jaci.2010.09.034) sets the indication threshold as moderate-to-severe allergic rhinitis or allergic asthma inadequately controlled by intranasal corticosteroids plus second-generation antihistamines, with demonstrable IgE sensitization. No Summary Statement in Cox 2011 PP3 contains a maximum age cutoff.
For adults weighing whether allergy shots fit their work and travel schedule, Curex's at-home IgE testing with board-certified allergist review identifies whether sensitization is single-allergen (often manageable with one of the four FDA-approved SLIT tablets) or multi-allergen (where compounded SCIT is indicated). For eligible multi-allergen adults, Curex provides at-home SCIT — a personalized serum sterile-compounded to USP <797> standards — at $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand before the first injection.
Three adult-specific considerations that do not appear prominently in pediatric pages are relevant here. First, cardiovascular comorbidities: beta-adrenergic blocker therapy (selective or non-selective) is a relative contraindication per Cox 2011 PP3 because it may impair the body's epinephrine response during treatment of a systemic reaction. ACE inhibitors may potentiate bradykinin-mediated angioedema during anaphylaxis. Neither drug is an absolute contraindication — the risk-benefit decision is individualized — but the allergist must be aware before prescribing SCIT. Second, autoimmune disease activity: active autoimmune disease is a relative contraindication; quiescent or stable autoimmune disease is not. Third, adherence: the Tkacz JP et al. MarketScan analysis (n=103,207 SCIT initiators; Curr Med Res Opin 2021;37(6):957–965; DOI 10.1080/03007995.2021.1903848) found that 23.9% of adults never returned after their first injection, and only 43.9% reached maintenance within 18 months. Adult self-directed adherence frequently underperforms parent-mediated pediatric compliance — removing the weekly clinic trip removes the most common dropout trigger.
Durham SR et al. (NEJM 1999;341:468–475) established the foundational long-term case for adult SCIT: 3 years of grass-pollen SCIT produced sustained clinical benefit persisting 3 years after discontinuation — a disease-modifying outcome that antihistamines and nasal steroids cannot replicate. The 30-minute post-injection observation window after every injection is real and important per Cox 2011 PP3; on Zoom-supervised doses an allergist monitors live, and for routine maintenance injections the prescribed epinephrine auto-injector is confirmed on hand so eligible adults can self-administer safely at home. UnitedHealthcare ended coverage of home-administered SCIT effective January 1, 2023 for commercial plans — Curex's $129/month all-inclusive cost covers the serum, supplies, and allergist oversight without copays or UHC plan dependence.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
The adult allergy shot timeline follows the same two-phase structure regardless of age, though occupational constraints and medication interactions may affect scheduling decisions. The total commitment from first injection to end of course is 3–5 years.
Starting doses from the most dilute end of the 5–6 vial dilution ladder, advancing at each weekly visit. The 30-minute post-injection observation period is required at each visit per Cox 2011 PP3. Most adults reach maintenance after approximately 25–30 weekly injections. Cluster regimens (Tabar AI et al., JACI 2005) can compress build-up to 4–8 weeks with multiple injections per visit.
Injections shift to every 2–4 weeks once the therapeutic maintenance dose is reached. Many US practices stabilize at a 4-week interval once tolerance is established. Adults in professional roles typically find maintenance scheduling more manageable than the weekly build-up phase, though each visit still requires a 30-minute observation period per Cox 2011 PP3.
Durham SR et al. (NEJM 1999;341:468–475) documented that 3 years of grass SCIT produced sustained clinical benefit 3 years after discontinuation. Completing the minimum recommended 3-year course is critical to unlocking this durable disease-modifying effect. Adults who discontinue prematurely (as 23.9% do after the first injection per Tkacz 2021) do not accumulate the full tolerance benefit.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
Local reactions at the injection site occur in roughly two-thirds of injections — arm swelling, redness, and itching are normal responses. Systemic reactions are rare but require the mandatory 30-minute post-injection observation per Cox 2011 PP3. Adults on beta-blockers have a blunted epinephrine response if a systemic reaction requires epinephrine treatment — a key risk-factor to discuss with the allergist before starting.
Frequently asked questions
Is there an age limit for starting allergy shots as an adult?
There is no formal upper age limit for allergy shots per the AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox et al., JACI 2011). Candidacy is determined by comorbidity profile, medication list, and expected benefit-to-risk ratio — not by chronological age. Bozek et al. (2016) demonstrated significant efficacy in adults aged 60–75 with grass pollen allergy in a double-blind placebo-controlled trial, one of the first to specifically include elderly patients. The main considerations in older adults are cardiovascular comorbidities (particularly beta-blocker and ACE inhibitor use, which affect the management of systemic reactions) and realistic assessment of whether a 3–5-year treatment course fits the patient's health trajectory.
Can adults on beta-blockers get allergy shots?
Beta-blocker use is a relative contraindication for SCIT per Cox 2011 PP3. Selective and non-selective beta-blockers may impair the patient's response to epinephrine if epinephrine is needed to treat a systemic allergic reaction during treatment — because beta-blockade can prevent the drug's vasopressor and bronchodilator effects. This is not an absolute contraindication; the risk-benefit decision is made on a case-by-case basis in discussion between the prescribing allergist and the patient's cardiologist. Adults with compelling cardiac indications for beta-blockers (e.g., reduced-ejection-fraction heart failure, certain arrhythmias) should have this discussion explicitly before starting SCIT.
How long does it take for adult allergy shots to work?
Most adults experience meaningful symptom improvement within 6–12 months of reaching the maintenance dose, per the AAAAI/ACAAI Practice Parameter Third Update (Cox et al., JACI 2011). Some partial benefit may appear earlier during the build-up phase. Full disease-modifying benefit — the durable remission that persists after stopping — requires completing the minimum 3-year treatment course (Durham SR et al., NEJM 1999;341:468–475). If no clinical benefit is evident after 12 months at a stable maintenance dose, the allergist should reassess allergen selection, dosing adequacy, and the patient's ongoing allergen exposure load before discontinuing.
What is the adult allergy shot dropout rate?
In the largest real-world study of adult SCIT adherence, Tkacz JP et al. (Curr Med Res Opin 2021;37(6):957–965; DOI 10.1080/03007995.2021.1903848) analyzed a MarketScan commercial insurance database sample of 103,207 SCIT initiators. They found that 23.9% never returned for a second injection after the first visit, and only 43.9% reached the maintenance phase within 18 months. The most commonly cited reasons for dropout include the burden of weekly clinic visits during the 24–28-week build-up phase, work or family scheduling conflicts, and perception of insufficient early benefit. Adults considering SCIT should factor this commitment into their decision before starting.
Do allergy shots help adult-onset allergies?
Yes. Allergy shots are effective for adult-onset allergic rhinitis, allergic asthma, and allergic conjunctivitis regardless of when the sensitization developed. Adult-onset allergic disease is common and can arise from new environmental exposures, de novo sensitization with aging, or re-emergence of childhood allergies. The mechanism of SCIT — inducing allergen-specific regulatory T cells and IgG4 blocking antibodies — functions the same regardless of when the allergy developed. The critical eligibility requirement is demonstrating IgE-mediated sensitization through skin testing or specific IgE blood testing before the allergist compounds the treatment vial, per Cox 2011 PP3.
Can adults with asthma receive allergy shots?
Adults with mild-to-moderate, well-controlled allergic asthma can receive allergy shots — and the evidence supports both symptom and medication reductions. The Cochrane review of 88 asthma SCIT trials (Abramson MJ et al., Cochrane 2010; DOI 10.1002/14651858.CD001186.pub2) found a number needed to treat (NNT) of approximately 3 to prevent asthma symptom deterioration. The critical contraindication is severe or poorly controlled asthma: Cox 2011 PP3 marks FEV1 persistently below 70% predicted despite pharmacotherapy as a threshold requiring caution or deferral. Asthma should be confirmed as controlled before each injection visit; most practices assess peak flow pre-injection in unstable patients.
Does UnitedHealthcare cover allergy shots for adults?
UnitedHealthcare commercial plans cover SCIT when administered in a physician's office under allergist supervision, covering the allergen extract and the injection procedure. UnitedHealthcare ended coverage of home- and self-administered SCIT effective January 1, 2023 for its commercial plans — a coverage exclusion specific to those plans. Adults who want home-administered SCIT and are on a UHC commercial plan may consider self-paying for a program like Curex ($129/month all-inclusive, no copays) as an alternative to clinic-based UHC-covered care. Coverage specifics for in-office SCIT — deductibles, copays, prior authorization requirements — vary by specific UHC plan; members should verify benefits before starting a course.
Related Articles
Allergy Shot Name: SCIT Defined & Explained | Curex
The clinical name for an allergy shot is subcutaneous immunotherapy (SCIT). There is no single brand name — each vial is custom-compounded. SLIT tablets have brand names; SCIT does not.
Read moreNames of Allergy Shots for Adults | Curex Guide
The clinical name is SCIT. Extracts come from Greer, ALK-Abelló, or Stallergenes Greer. FDA-approved branded tablets: Grastek, Oralair, Ragwitek, Odactra.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.